About this trial
Bile leakage (BL) is the most frequent complication after liver resection. This study is to investigate the role of intraoperative administration of SMOFlipid 20% (fat emulsion which allows intraoperative identification of open bile ducts at the liver resection surface when it is administered retrograde through the cystic duct) in terms of prevention of postoperative BL within 30 days after surgery.
Eligibility criteria
Qualifiers
Patients who will receive an anatomical resection of two or more liver segments for any reason with simultaneous cholecystectomy in elective Setting
Patients who will receive an anatomical resection of two or more liver segments for any reason which already had a cholecystectomy if intraoperatively the cystic stump can be identified and opened
Ability of subject to understand character and individual consequences of the clinical Trial
Informed consent documented by signature
Disqualifiers
Previous cholecystectomy if intraoperative it is not possible to identify the cystic stump
Intraoperative hepatico-jejunostomy
Hypersensitivity to fish-, egg-, soybean or peanut protein or to any of the active ingredients or excipients
Immunosuppression, pregnancy
Trial design
Treatments tested in this trial
- "white" test" (= the administration of SMOFlipid retrograde through the cystic duct)
Treatment groups
Sponsors and collaborators
Giulia Manzini
Lead sponsor
Kantonsspital Aarau
Sponsor institution